Scope
NICE guidance on initiating and managing strong opioids for pain in adults with advanced progressive disease. It links patient education and frequent review to oral morphine titration, route selection, rescue medication and active management of predictable adverse effects. This summary does not replace specialist assessment when organ impairment or difficult pain control complicates prescribing.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Prepare the patient and carer
- Ask patients with advanced progressive disease about fears concerning addiction, tolerance, adverse effects, or the belief that starting a strong opioid necessarily means the final stage of life. [1]
- Provide spoken and written instructions covering the purpose and expected effect of treatment, regular and breakthrough dosing, toxicity, safe storage, follow-up prescriptions and out-of-hours contacts, especially when treatment begins. [1]
- Arrange access to frequent review of pain relief and adverse effects. During titration, adjust the dose to balance acceptable relief with tolerability, and seek specialist advice if repeated adjustments do not achieve that balance. [1]
Start and titrate oral morphine
- When initiating a strong opioid in advanced progressive disease, offer regular oral immediate-release or sustained-release morphine according to patient preference, with immediate-release oral morphine for breakthrough pain. [1]
- For patients without renal or hepatic comorbidity, a typical starting total is 20–30 mg oral morphine daily, with 5 mg immediate-release oral morphine as rescue during titration. The stated sustained-release example is 10–15 mg twice daily. [1]
- Obtain specialist advice before prescribing strong opioids when renal or hepatic impairment is moderate to severe. Do not extend the usual starting schedule to this group without that advice. [1]
Choose maintenance treatment and route
- Offer sustained-release oral morphine as the first maintenance treatment for advanced progressive disease requiring strong opioids. If pain remains poorly controlled after optimisation, review the analgesic strategy and consider specialist advice. [1]
- Do not routinely use an opioid patch as the first maintenance option when oral treatment is suitable. If the oral route is unsuitable and analgesic needs are stable, consider a transdermal patch, with specialist support where needed. [1]
- When oral opioids are unsuitable and analgesic requirements are unstable, consider a subcutaneous opioid with specialist support as needed. NICE’s choice among these options includes acquisition cost; that wording reflects its health-system context. [1]
Provide rescue medication and reassess persistent pain
- For patients maintained on oral morphine, use immediate-release oral morphine as the first rescue treatment for breakthrough pain. [1]
- Do not select fast-acting fentanyl as first-line rescue treatment. Consider specialist advice if pain remains inadequately controlled despite treatment optimisation. [1]
Prevent constipation and manage nausea
- Explain that constipation affects nearly everyone taking strong opioids and prescribe regular laxative treatment at an effective dose from the start. [1]
- Explain that laxatives take time to work and adherence matters. Optimise the laxative regimen before considering an opioid switch for constipation. [1]
- Warn that nausea can occur after starting treatment or increasing the dose and is often temporary. If it persists, prescribe and optimise an antiemetic before considering a change of opioid. [1]
Respond to sedation and impaired concentration
- Explain that mild drowsiness or impaired concentration after initiation or a dose increase is often transient. Warn that impaired concentration can affect driving and other manual tasks. [1]
- For persistent or moderate-to-severe central nervous system effects, consider dose reduction if pain is controlled, or an opioid switch if pain is uncontrolled. Seek specialist advice if adverse effects remain uncontrolled despite optimisation. [1]
Limitations and use
- The recommendations concern adults with advanced progressive disease, not every chronic pain presentation.
- The replaced controlled-drug recommendation and linked technology appraisals were not reproduced here. The extract does not establish their complete prescribing criteria.
- Acquisition-cost and driving references reflect the UK guideline; local prescribing and legal requirements still apply.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Palliative care for adults: strong opioids for pain relief
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 23 May 2012
- Publisher’s latest update
- 3 August 2016
- Resource type
- Clinical guideline · House clinical summary
- Source setting
- United Kingdom
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.